Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1,831 Mln
P/E Ratio
--
P/B Ratio
4.56
Industry P/E
--
Debt to Equity
0.02
ROE
-0.74 %
ROCE
-64.53 %
Div. Yield
0 %
Book Value
3.52
EPS
-2.07
CFO
$-514.11 Mln
EBITDA
$-533.58 Mln
Net Profit
$-766.06 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Centessa Pharmaceuticals (CNTA)
| -18.09 | -5.96 | -17.30 | 53.81 | 15.74 | -- | -- |
|
BSE Sensex
| 2.61 | 3.71 | 5.78 | 8.89 | 11.76 | 20.11 | 11.35 |
|
2024
|
2023
|
2022
|
2018
|
|
|---|---|---|---|---|
|
Centessa Pharmaceuticals (CNTA)
| 109.15 | 156.77 | -72.47 | 0.00 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 5.87 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 38.55 | 10,593.45 | 21.84 | 23.13 | |
| 306.35 | 8,570.17 | 22.78 | 66.44 | |
| 27.82 | 10,589.59 | -- | -28.77 | |
| 107.24 | 10,559.67 | 32.44 | 14.16 |
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines. Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of... idiopathic hypersomnia and narcolepsy type 1 and 2. The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as well as other potential symptoms, including excessive daytime sleepiness, impaired attention, cognitive deficits, and fatigue; and ORX489 for the treatment of neuropsychiatric disorders. In addition, it offers LockBody, which is designed to selectively drive potent effector function activity, such as CD3, into the tumor microenvironment. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom. Address: 1 Ashley Road, Altrincham, United Kingdom, WA14 2DT Read more
CEO & Director
Dr. Saurabh Saha M.D., Ph.D.
CEO & Director
Dr. Saurabh Saha M.D., Ph.D.
Headquarters
Altrincham
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Centessa Pharmaceuticals plc (CNTA) stood at $ 577 Mln as on 31-Dec-24
The share price of Centessa Pharmaceuticals plc (CNTA) is $13.72 (NASDAQ) as of 29-Apr-2025 16:00 EDT. Centessa Pharmaceuticals plc (CNTA) has given a return of 15.74% in the last 3 years.
Centessa Pharmaceuticals plc (CNTA) has a market capitalisation of $ 1,831 Mln as on 29-Apr-2025. As per Value Research classification, it is a company.
Since, TTM earnings of Centessa Pharmaceuticals plc (CNTA) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Centessa Pharmaceuticals plc (CNTA) and enter the required number of quantities and click on buy to purchase the shares of Centessa Pharmaceuticals plc (CNTA).
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines. Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2. The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as well as other potential symptoms, including excessive daytime sleepiness, impaired attention, cognitive deficits, and fatigue; and ORX489 for the treatment of neuropsychiatric disorders. In addition, it offers LockBody, which is designed to selectively drive potent effector function activity, such as CD3, into the tumor microenvironment. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom. Address: 1 Ashley Road, Altrincham, United Kingdom, WA14 2DT
The CEO & director of Dr. Saurabh Saha M.D., Ph.D.. is Centessa Pharmaceuticals plc (CNTA), and CFO & Sr. VP is Dr. Saurabh Saha M.D., Ph.D..
There is no promoter pledging in Centessa Pharmaceuticals plc (CNTA).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Centessa Pharmaceuticals plc (CNTA) | Ratios |
|---|---|
|
Return on equity(%)
|
-73.93
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Centessa Pharmaceuticals plc (CNTA) was $0 Mln.
$-0.03
(
